Inhibikase Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q4 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Inhibikase Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q4 2021 to Q2 2024.
  • Inhibikase Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $164K, a 40.9% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $164K -$113K -40.9% Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $193K -$110K -36.2% Mar 31, 2024 10-Q 2024-05-15
Q4 2023 $222K -$106K -32.4% Dec 31, 2023 10-Q 2024-08-14
Q3 2023 $250K -$103K -29.2% Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $277K Jun 30, 2023 10-Q 2023-08-14
Q1 2023 $303K Mar 31, 2023 10-Q 2023-05-15
Q4 2022 $329K +$329K Dec 31, 2022 10-K 2024-03-27
Q3 2022 $353K Sep 30, 2022 10-Q 2022-11-14
Q4 2021 $0 Dec 31, 2021 10-K 2023-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.